Once registered, you can:

  • - Read additional free articles each month
  • - Comment on articles and featured creative work
  • - Get our curated newsletters delivered to your inbox

By registering you agree to our privacy policy, terms & conditions and to receive occasional emails from Ad Age. You may unsubscribe at any time.

Are you a print subscriber? Activate your account.

Leo Burnett scoops new drug in Germany

Published on .

BAD HOMBURG -- Pharmaceutical company Lilly Deutschland, subsidiary of the U.S. Eli Lilly, has appointed Michael Conrad & Leo Burnett, Frankfurt, to handle its innovative prescription drug Evista.

The agency triumphed over Wilkens, Hamburg, to pick up its first prescription-only drug account. In the U.S., the Evista business is held by Leo Burnett Chicago.

Evista is a new drug, to be prescribed by doctors, which works to prevent osteoporosis without the risk of breast or womb cancer as a side-effect because it does not contain oestrogen.

Lilly Deutschland says Evista still has to be approved by the European Medicines Evaluation Agency in London, which is currently considering the application and is expected to grant approval next year. In the U.S., Eli Lilly is also awaiting approval for the drug.

Copyright August 1997, Crain Communications Inc.

Most Popular
In this article: